Skip to main content Help with accessibility Skip to main navigation

RITUXIMAB (MabThera®) for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated (ANCA) Vasculitis (AAV)

CCG Approval Status:

Date Added: 15 - Nov - 2017
Body System:
NHS England

NHS England specialised commissining resources: the clinical reference group responsible for specialised rheumatology has published a commissioning policy that defines access to a particular service for a cohort of patients.